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Abstract
Background: Blastocystis species are common enteric human parasites and carriage has been linked to Irritable
Bowel Syndrome (IBS), particularly diarrhoea-predominant IBS. The spectrum of immune reactivity to Blastocystis
proteins has been reported previously in symptomatic patients. We investigated differences in serum
immunoglobulin profiles between patients with IBS, both positive and negative for Blastocystis carriage, and healthy
controls (HC).
Methods: Forty diarrhoea-predominant IBS patients (26 patients positive for Blastocystis sp., 14 negative patients)
and forty HC (24 positive, 16 Blastocystis-negative) were enrolled. Age, gender, ethnicity and serum immunoglobulin
A (IgA) levels were recorded and faecal specimens were analysed using smear, culture and polymerase chain
reaction amplification of ribosomal DNA. Sera were tested in Western blots and the reactivities compared to known
targets using monoclonal antibodies Blastofluor® (Blastocystis specific antibody), MAb1D5 (cytopathicto Blastocystis
cells), anti-promatrix metalloprotease-9 (anti-MMP-9) and SDS-PAGE zymograms.
Results: Levels of serum IgA were significantly lower in Blastocystis carriers (p < 0.001) but had no relationship to
symptoms. Western blots demonstrated serum IgG antibodies specific for Blastocystis proteins of 17,27,37,50,60-65,
75–90, 95–105 and 150 kDa MW. Reactivity to the 27, 50 and 75-95 kDa proteins were found more frequently in the
IBS group compared to the HC’s (p < 0.001) and correlation was greater for Blastocystis-positive IBS patients (p < 0.001)
than for negative IBS patients (p < 0.05). MAb1D5 reacted with proteins of 27 and 100 kDa, and anti-MMP-9 with 27, 50
and 75-100 kDa proteins. Bands were seen in zymograms around 100 kDa.
Conclusions: Low serum IgA levels are associated with Blastocystis carriage. All IBS patients were more likely
to demonstrate reactivity with Blastocystis proteins of 27 kDa (likely a cysteine protease), 50 and 75-95 kDa MW
compared to HC. The presence of antibodies to these Blastocystis proteins in some Blastocystis-negative subjects
suggests either prior exposure to Blastocystis organisms or antibody cross reactivities. The anti-proMMP-9 reaction at
50 and 75–100 kDa and the zymogram result suggest that metalloproteases may be important Blastocystis antigens.
Trial registration: Australian and New Zealand Clinical Trials registry ACTRN: 12611000918921
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Background
Irritable bowel syndrome (IBS) is a common clinical
condition affecting up to 10 % of the global population
and characterised by abdominal pain, bloating and dis-
turbance of bowel habit [1]. The underlying cause of IBS
is not known although differences in gut motility, the
enteric immune and nervous system, intestinal perme-
ability, systemic cytokine production, faecal protease ex-
cretion, faecal microflora and psychological profiles have
been reported in this condition [2]. The disease is de-
fined by a clinical symptom complex description (Rome
III) [3] that has a sensitivity of 70 % and a specificity of
80 % in differentiating IBS patients from patients with
other gastrointestinal diseases [4]. This clinical definition
is the gold standard, but assessment can be subjective.
Reliable, clinically applicable IBS biomarkers, particularly
if they direct therapeutic choices, would be useful.
Serum biomarkers for IBS have been investigated in two
previous studies [5, 6] and both were less accurate than
using the Rome III criteria. Post-infectious IBS is known
to comprise 10 % of the total cases of IBS and this has
stimulated interest in the faecal microbiota as a possible
contributing cause of IBS [7]. The carriage of the enteric
organism Blastocystis has been reported to be three
times higher in patients with diarrhoea predominant IBS
(D-IBS) compared to healthy controls [8], making it an
organism of interest in IBS.
Blastocystis sp. are the most common parasites found
in human stool [9]. Sub-typing of the18S ribosomal
DNA(rDNA) has identified 17 different subtypes (ST’s)
and nine have been identified in humans [10, 11].
Carriage of Blastocystis sp. is increased in patients with
various types of immunosuppression [9] and in patients
with irritable bowel syndrome [8]. Nevertheless, many
carriers are healthy and a definite association between
carriage and illness has not been proven in epidemio-
logical studies [12].
Blastocystis sp. reside in the intestinal lumen, estab-
lishing in the ileum and caecum adherent to the outer
layer of mucus [13, 14], with only rare reports of muco-
sal invasion. Antibodies specific for Blastocystis antigens
have been demonstrated in the faeces and the serum of
carriers [15–19] and antibody titres have been reported
to be higher with length and severity of infection [15].
These antibodies have been described in all immuno-
globulin classes. IgA antibodies specific forBlastocystis
sp. have been shown to be present in pig faeces [19] and
in both faeces and serum of infected humans [20]. Our
previous pilot study demonstrated lower serum IgA
levels in IBS patients positive for Blastocystis carriage
than in other patient groups or healthy controls [21].
Blastocystis specific immunoglobulin G (IgG) anti-
bodies have also been detected in serum [15, 20, 22] and
faeces of Blastocystis infected humans [20], with lower
titres in the latter compartment. Using SDS-PAGE and
Western blot analysis, serum IgG has been reported to
react with Blastocystis-specific proteins of 12 kDa [16],
29 kDa, 50 kDa and 118 kDa molecular weights (MWs)
[17]. Antibody reactivity to a 29 kDa MW Blastocystis
protein has been reported to be more common in the
serum of symptomatic patients compared to asymp-
tomatic individuals [18], and subsequent protein
sequencing of a 30 kDa protein showed it to possess
50 % homology with known cysteine protease (legu-
main type) peptide sequences [23]. A monoclonal IgM
antibody 1D5 (MAb1D5), known to be cytopathic to
Blastocystis organisms [24] as well as a human legu-
main antibody both bind to this 30 kDa Blastocystis
antigen in Western blots.
Protease secretion is a recognised virulence mech-
anism for parasites [25] facilitating tissue/cell inva-
sion, protein activation and immunoevasion. These
molecules are also highly immunogenic. Analysis of
the genome of Blastocystis ST7 has led to the predic-
tions that the parasite would be able to produce all
major classes of proteases, including serine proteases,
metalloproteases and perhaps as many as 20 different
cysteine proteases [26, 27]. Notably Blastocystis prote-
ases have been shown to cleave human secretory IgA
[28] and induce production of the pro-inflammatory
cytokine interleukin-8 (IL-8) by enterocytes in an
in vitro model system [29].
Our aim was to explore the clinical relevance of
Blastocystis sp. in patients with diarrhoea predomin-
ant IBS by assessing serum antibody reactivities
specific for Blastocystis. In this study we compared
the serum IgA levels in IBS patients, either positive
(IBS-P) or negative (IBS-N) for Blastocystis carriage,
and healthy controls (positive (HC-P) and negative
(HC-N) for Blastocystis). IgG serological responses to
specific Blastocystis antigens were examined in all
these subgroups using Western blotting techniques.
Identification of specific Blastocystis antigens was
attempted by probing the Western blots with Blastocystis
specific antibody (Blastofluor®, Antibodies Inc), MAb1D5
and pro-matrix metalloprotease 9 (anti-MMP-9) antibody.
Methods
Study outline
Forty patients presenting with diarrhoea-predominant
IBS to the Toowoomba Gastroenterology Clinic and
forty healthy volunteers were enrolled in the study and
signed written consent forms. The study was approved
by the University of Queensland Medical Research
Ethics Committee and was part of a clinical trial that is
registered with the Australian and New Zealand Clinical
Trials registry (http://www.ANZCTR.org.au) ACTRN:
12611000918921. Single baseline faecal and serum
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samples were collected from all participants. Total
serum IgA levels were measured in all participants and
faecal and serum specimens underwent further microbio-
logical, molecular and Western blot analysis.
Ethical approval
The study was approved by the University of Queensland
Medical Research Ethics Committee (No 2011000454).
Inclusion protocol
Adult patients presenting with chronic diarrhoea and
abdominal pain from 1/8/11 to 20/02/14 were assessed
clinically. Baseline blood tests, including full blood count,
serum calcium, thyroid function tests, serum IgA and
coeliac antibody tests were performed. Other pathogens
known to cause chronic diarrhoea such as Salmonella
sp, Shigella sp, Vibriosp., Campylobacter sp, Aeromo-
nas sp),Giardia duodenalis, Clostridium difficule and
Dientamoebahistolytica were excluded with faecal mi-
croscopy , culture and PCR testing performed by a
commercial pathology laboratory. All patients pro-
ceeded to an upper and lower endoscopy that in-
cluded gastric antral, duodenal, ileal and colonic
biopsies. Forty eligible symptomatic patients who had
no other cause for symptoms and who fulfilled the Rome
criteria [30] for diarrhoea predominant IBS were enrolled
in the study. Of these, 26 patients were positive for Blasto-
cystis (IBS-P) and 14 were negative (IBS-N). Forty healthy
volunteers working at the University of Queensland and
with no gastrointestinal symptoms in the preceding
12 months were tested for Blastocystis sp. infection, 24
were positive (HC-P) and 16 were negative (HC-N).
Details of age, gender and ethnicity of participants were
recorded.
Exclusion protocol
Only non-pregnant adults between 18 and 75 years of
age were recruited for the study. Patients with significant
systemic diseases or co-morbidities were excluded.
Diagnosis of Blastocytis infection
All samples were run in parallel for the presence of
Blastocystis sp. using a simple unstained wet faecal
smear, xenic in vitro culture (XIVC) and PCR
(confirmed as Blastocystis sp. using DNA sequencing).
A study participant was considered to be positive if
any one of the tests was positive as described previ-
ously [21].
Serum Immunoglobulin A
Serum samples were stored at −20 °C prior to analysis at
Sullivan and Nicolaides Pathology Service, Brisbane,
Queensland using a Siemens BNII Nephelometer
(Siemens, Munich, Germany) and Siemens reagents.
Western blotting
Antigen preparation
An axenic strain of Blastocystis sp. ST4 (WR1) was cul-
tured anaerobically in pre-reduced Iscove’s Modified
Dulbecco’s medium (IMDM) (Sigma-Aldrich, St Louis,
USA: 13390) enriched with 10 % heat-inactivated horse
serum (Gibco: 26050088). WR1 was originally obtained
from the stool of Wistar rats in Singapore but has been
in continuous axenic culture for more than seventeen
years. Blastocystis antigen was prepared using the pro-
teinase inhibitor Complete Lysis-B (2x), EDTA-free kit
(Roche, Mannheim, Germany:04719948001) and stored
at −20 °C until required.
SDS-PAGE protocol
Approximately 300 ng of Blastocystis antigen was mixed
with equal volumes of loading buffer (Laemmli sample
buffer mixed with 2 M 2-mercaptoethanol in a ratio of
19:1vol:vol (Bio- Rad, California, USA)) and loaded into
the large well of a preparative 4-15 % Tris–HCl Ready
Gel (Bio-Rad: 161–1140). A separate single protein
standard ladder well in the gel was loaded with 15uL of
Precision Plus Protein Western C Standard (Bio-Rad:
161–0385). The gel was electrophoresed in M Tris/
Glycine/SDS buffer (Bio-Rad: 161–0732) at 100 V for
40–60 min at room temperature and then rinsed
three times with deionised water. The proteins were
transferred to a nitrocellulose membrane using 1 M
Tris/Glycine/20 % methanol buffer electrophoresed at
100 V for 60 min at 4 °C. The membrane was rinsed
three times with 0.1 % 1Mphosphate buffered saline
(PBS)/Tween 20 (PBST) (Sigma Aldrich, St Louis,
USA: P5927) solution and then blocked in 100 ml of
blocking solution (0.1 % PBST, 4g skim milk and1g bovine
serum albumin per 100 ml (Sigma Aldrich: A2153) for
60 min at room temperature. The membrane was cut into
strips and stored at −20 °C till required.
Immunolabeling protocol
Membrane strips were incubated with primary anti-
body (patient sera or MAbs) diluted in 1 mL of Signal
Boost™Immunoreaction Enhancer Kit (Calbiochem,
Darstadt, Germany: 407207) Solution One for 24 h on
a rocker platform at 4 °C before washing consecutively
three times for 15 min in PBST. The strips were then
incubated with secondary antibody diluted in Signal
Boost Solution Two at room temperature for 1 h on a
rocker platform and the washing steps repeated.
The patient sera were diluted 1:10 and the secondary
antibody was a 1: 2000 dilution of horseradish peroxid-
ase (HRP)-conjugated goat anti-human IgG Ab (Sigma
Aldrich:A8786).
An additional four antibodies were tested for reactiv-
ity with the Blastocystis antigens:(i) a mouse derived
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Blastocystis-cytopathic monoclonal IgM antibody, MAb1D5
(purified Mab against surface legumain of Blastocystis
ST7, IgM, 16 μg/μL) [27, 31, 32], (ii) a control unrelated
mouse derived monoclonal IgM antibody, MAb5, (iii) a
rabbit polyclonal anti-Blastocystis ST3 antibody (Blasto-
fluor®) [33],and (iv) a rabbit polyclonal anti-human matrix
metalloproteinase 9 (Anti-MMP-9) (Calbiochem: 444236).
These primary antibodies were diluted 1:100, and the sec-
ondary antibodies1:1000, using HRP-conjugated-goat anti-
mouse IgM (Sigma, St Louis, USA: Cat no: A8786) and
HRP-conjugated anti-rabbit polyclonal Ab, respectively.
All blots were run with a protein standard ladder and
a negative control. Negative controls were prepared ac-
cording to the protocol above except exclusion of
serum/primary antibody in step one followed by incuba-
tion with the secondary antibody.
The antibody binding was visualized using Clarity
Western ECL Substrate (Bio Rad, California USA) and a
Bio Rad Chemi-DocTM XRS Gel Documentation system.
The brightness and contrast was adjusted over entire
images to optimise the image but no differential image
manipulation was used on separate lanes.
Zymograms
The Blastocystis antigen was prepared as per the Western
blotting protocol and combined with Zymogen buffer
(Bio-Rad: 161–0764) in a vol:vol ratio of 1:1. Approxi-
mately 50 ng of buffered Blastocystis antigen was loaded
into each well of a 10 % gelatin Ready Gel® Zymogram Gel
(Bio-Rad: 161–1167) and the gel was electrophoresed in
1 M Tris/Glycine/SDS buffer (Bio-Rad: 161–0732) at 90 V
for 40–60 min at room temperature. The gel was cut in
half and both gels subjected to renaturation and develop-
ment steps. The gels were incubated in 100 mL of Zymo-
gen Renaturation buffer (Bio-Rad: 161–0765) for 1 h at
room temperature on a rocker platform and then in-
cubated in 100 mL of Zymogen Development buffer
(Bio-Rad: 161–0766) for 24 h at 37 °C without or with
protease inhibitor, 1 mM EDTA (ethylenediaminetetraace-
tic acid), added to the two solutions for one gel. The buf-
fer was decanted and the gels were stained with 100 mL
Aqua® stain (Bulldog Bio, Portsmouth, UK) for 15 min on
a rocker platform and rinsed with deionised water.
Statistical analysis
Statistical analysis was carried out using SPSS v.22 [34].
The level of IgA was transformed using natural loga-
rithm to get a normal distribution. A one-way Analysis
of Covariance (ANCOVA) was used to compare the level
of IgA between the four groups, adjusting for poten-
tial confounders, such as seasonality [35]. Pearson’s
chi-square/ Fisher exact test were used to assess the
significance of association between subjects with IBS
and healthy controls with the presence of serum IgG




The eighty study participants comprised forty symptom-
atic IBS patients (26 positive and 14 negative for Blastocys-
tis carriage) and forty asymptomatic healthy controls (24
positive and 16 negative for Blastocystis). The average par-
ticipants’ age was 45.2 ± 14.4 years (range 16–75 years).
There were no significant between-group differences in
terms of age (F(3,76) = 0.81, p = 0.49) and gender distribu-
tion (λ2 = 4.37, p = 0.22). However, there were significantly
more Caucasians compared to non-Caucasians in the IBS-
P, IBS-N and HC-P groups (λ2 = 16.83, p = 0.001). The
Blastocystis sp. subtypes detected were ST3 (34 %), ST4
(26 %), ST1 (16 %), ST2 and ST7 (8 %), ST8 (6 %) and
ST5 (2 %). Characteristics of the 80 subjects and their
Blastocystis subtypes are given in Tables 1 and 2.
Serum IgA levels
Serum IgA levels were higher in male (2.36 ± 1.36 g/L)
compared to female participants (1.79 ± 1.09 g/L) (t = 4.15,
Table 1 Demographic and epidemiological characteristic of
subgroups
IBS-P IBS-N HC-P HC-N
(n = 26) (n = 14) (n = 24) (n = 16)
Age (years; mean ± SD) 44.5 ± 15.2 44.5 ± 14.2 48.7 ± 13.2 41.7 ± 15.0
Female (n, %) 19 11 12 11
Caucasian (n, %) 26 (100) 13 (93) 21 (88) 9 (56)
Season recruited (n)
Spring 2 3 19 0
Summer 8 5 4 1
Autumn 11 4 0 7











(g/L; mean ± SD)
1.63 ± 0.95 2.19 ± 1.01 1.54 ± 0.76 3.06 ± 1.61
SD: standard deviation
IBS-P/N: Irritable bowel syndrome subjects positive/negative for Blastocystis
HC-P/N: Healthy control subjects positive/negative for Blastocystis
ST: subtype; IgA: Immunoglobulin A
a unadjusted mean; results IgA of different subtypes in IBS-P & HC-P groups
were pooled for analysis purpose
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p < 0.05). Levels of IgA were not found to be different be-
tween Caucasian and Asian participants, nor across the
different Blastocystis subtypes (both p > 0.05).
The average level of serum IgA was lowest in the HC-P
group, followed by IBS-P, IBS-N and HC-N (Table 1). Par-
ticipants who tested Blastocystis-positive (combined IBS-P
and HC-P subgroups) had a significantly lower serum IgA
level (1.59 ± 0.54 g/L) than their Blastocystis- negative
counterpart (combined IBS-N and HC-N) subgroups
(2.65 ± 1.41 g/L) (t(78) = 4.06, p < 0.001). Planned con-
trasts revealed that participants in the HC-N group
had significantly higher serum IgA levels compared to
those in the IBS-P group, t(75) = −3.31, p = 0.001, and
HC-P group, t(75) = −4.30, p < 0.001. Pairwise compar-
isons showed that IgA levels in IBS-N participants
were higher than those in the HC-P group (p < 0.01).
There was a significant difference in IgA levels be-
tween the four groups after controlling for the potential
confounding effect of seasonality and gender, F(3,73) =
9.05, p < 0.001. The gender covariate was significantly re-
lated to the level of IgA, (F(1,73) = 7.93, p < 0.01),
whereas seasonality, was not (F(1,75) = 3.42, p = 0.07).
Blastocystis-specific serum IgG antibody bands
Western blots were employed to assess the serum IgG re-
sponse to Blastocystis proteins in the four clinical groups
and the analysis of these results is shown in Tables 2, 3 and
4. Reactivity was seen to Blastocystis proteins of approxi-
mately 27, 50, 60–65, 75–90, 95–105 and 150kDaMW [36]
in all groups of patients (Figs. 1, 2, 3). These results were
examined to assess whether serum reactivity to Blastocystis
proteins of different sizes was associated with carriage of a
particular subtype of Blastocystis sp., or either the presence
of Blastocystis sp. orIBS symptoms. If Blastocystis sp. were
to prove to be a cause of IBS then it is possible that IBS-
N patients may have had Blastocystis infection in the
relatively recent past and the subgroups with IBS
were analysed separately in order to reduce any con-
tribution from pre-existing antibodies (Table 4).
The numbers of Blastocystis-positive subjects in each
subtype group were small but serum reactivity to all the
protein bands was present in every subtype with the ex-
ception of 17 kDa, 37 kDa and 150 kDa bands (Table 2).
No significant associations were found between Blasto-
cystis sp. subtypes and reactivity to particular protein
bands based on Fisher’s exact test results (all p > 0.05).
Table 2 Serum antibody reactions to Blastocystis antigens detected by Western immunoblotting in all subjects infected with
different subtypes of Blastocystis
Table 3 Serum antibody reactions to Blastocystis antigens





Number of subjects with presence of protein bands (n, %)
IBS-P (n = 26) IBS-N (n = 14) HC-P (n = 24) HC-N (n = 16)
17 kDa 1 (4) 0 (0) 5 (21) 0 (0)
27 kDa 25 (96) 12 (86) 17 (71) 7 (44)
37 kDa 3 (12) 0 (0) 3 (13) 0 (0)
50 kDa 26 (100) 13 (93) 16 (67) 8 (50)
60-65 kDa 26 (100) 12 (86) 19 (80) 13 (81)
75-90 kDa 25 (96) 13 (93) 14 (58) 9 (56)
95-105 kDa 14 (54) 3 (21) 14 (58) 2 (13)
150 kDa 5 (19) 1 (7) 16 (67) 1 (6)
IBS-P/N: Irritable bowel syndrome subjects positive/negative for Blastocystis
HC-P/N: Healthy control subjects positive/negative for Blastocystis
n: number kDa: kiloDalton
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Table 4 Comparison of presence of Blastocystis and/or gastrointestinal symptoms to specific sized antibody bands directed against Blastocystis proteins using Western
immunoblotting
Presence of antibody to Blastocystis protein at band MW (n, %)
Gp1 Gp2 17 kDa 27 kDa 37 kDa 50 kDa 60-65 kDa 75-90 kDa 95-105 kDa 150 kDa
Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 Gp1 Gp2 Gp1 Gp2
Blastocystis presence
IBS-P & HC-P (n = 50) IBS-N & HC-N (n = 30) 6 (12) 0 (0)* 42 (84) 19 (63)* 6 (12) 0 (0)* 42 (84) 21 (70) 45 (90) 25 (83) 39 (78) 22 (73) 28 (56) 5 (17)*** 21 (42) 2 (7)***
IBS-P & HC-P (n = 50) HC-N (n = 16) 6 (12) 0 (0) 42 (84) 7 (44)*** 6 (12) 0 (0) 42 (84) 8 (50)** 45 (90) 13 (81) 39 (78) 9 (56) 28 (56) 2 (13)** 21 (42) 1 (6)**
IBS-P (n = 26) IBS-N (n = 14) 1 (4) 0 (0) 25 (96) 12 (86) 3 (12) 0 (0) 26 (100) 13 (93) 26 (100) 12 (86)* 25 (96) 13 (93) 14 (54) 3 (21)* 5 (19) 1 (7)
HC-P (n = 24) HC-N (n = 16) 5 (21) 0 (0)^ 17 (71) 7 (44) 3 (13) 0 (0) 16 (67) 8 (50) 19 (79) 13 (81) 14 (58) 9 (56) 14 (58) 2 (13)** 16 (67) 1 (6)***
GIT symptoms
IBS-P & IBS-N (n = 40) HC-P & HC-N (n = 40) 1 [56] 5 (13) 37 (93) 24 (60)*** 3 (8) 3 (8) 39 (98) 24 (60)*** 38 (95) 32 (80)* 38 (95) 23 (58)*** 17 (43) 16 (40) 6 (15) 17 (43)**
IBS-P (n = 26) HC-P & HC-N (n = 40) 1 (4) 5 (13) 25 (96) 24 (60)*** 3 (12) 3 (8) 26 (100) 24 (60)*** 26 (100) 32 (80)* 25 (96) 23 (58)*** 14 (54) 16 (40) 5 (19) 17 (43)*
IBS-P (n = 26) HC-P (n = 24) 1 (4) 5 (21) 25 (96) 17 (71)* 3 (12) 3 (13) 26 (100) 16 (67)*** 26 (100) 19 (80)* 25 (96) 14 (58)*** 14 (54) 14 (58) 5 (19) 16 (67)***
IBS-P (n = 26) HC-N (n = 16) 1 (4) 0 (0) 25 (96) 7 (44)*** 3 (12) 0 (0) 26 (100) 8 (50)*** 26 (100) 13 (81)* 25 (96) 9 (56)*** 14 (54) 2 (13)** 5 (19) 1 (6)
IBS-N (n = 14) HC-P & HC-N (n = 40) 0 (0) 5 (13) 12 (86) 24 (60) 0 (0) 3 (8) 13 (93) 24 (60)* 12 (86) 32 (80) 13 (93) 23 (58)* 3 (21) 16 (40) 1 (7) 17 (43)*
IBS-N (n = 14) HC-N (n = 16) 0 (0) 0 (0) 12 (86) 7 (44)* 0 (0) 0 (0) 13 (93) 8 (50)* 12 (86) 13 (81) 13 (93) 9 (56)* 3 (21) 2 (13) 1 (7) 1 (6)
Gp: group of study subjects; n: number of subjects; kDa: kiloDalton; MW: molecular weight
IBS-P/N: Irritable bowel syndrome subjects positive/negative for Blastocystis
HC-P/N: healthy control subjects positive/negative for Blastocystis











Reactivity with proteins of approximately 17 and
37 kDa MW were observed in 7.5 % of total participants
and these were only present in those subjects who tested
positive for the presence of Blastocystis sp. Proportions
of participants with reactivity for proteins of 95-105 kDa
and 150 kDa MW, were significantly lower in the
combined Blastocystis-negative group(λ2 = 11.97, p ≤ 0.001
and λ2 = 11.43, p ≤ 0.001 respectively) (Table 3). The associ-
ation of antibody-reactivity to the 95–105 kDa protein(s)
with Blastocystis carriage was statistically significant in the
intra-subgroup comparisons in both HC and IBS groups
(p ≤ 0.05) (Table 4).
Reactivity to the 27, 50 and 75–90 kDa MW bands
were detected in descending order of frequency in the
IBS-P group (96 %, 100 %, 96 %), the IBS-N group
(86 %, 93 %, 93 %), the HC-P (71 %, 67 %, 58 %) and the
HC-N (44 %, 50 %, 56 %) groups (Table 3). Reactivity to
each of these three proteins was found to be signifi-
cantly associated with IBS symptoms, regardless of
Blastocystis status (combined IBS-P + IBS-N(p ≤ 0.001),
IBS-P (p ≤ 0.001) or IBS-N(p < 0.05), respectively, ver-
sus HC: Table 4).
Further Analysis of the Blastocystis Antigens
The Blastofluor® antibody was tested in parallel with
IBS-P and HC-P sera on a Western blot and showed
reactivity with all the protein bands noted in the
Fig. 1 Serum antibodies from Blastocystis positive clinical subgroups IBS-P and HC-P reacting with Blastocystis proteins in Western blot
Fig. 2 Serum antibodies from Blastocystis–positive clinical subgroups IBS-P and HC-P, and Blastofluor® Ab reacting with Blastocystis proteins in
Western blot
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study subgroups, namely 17, 27, 37, 50, 60–65, 75–
90, 95–105, 150 and 250 kDa MW (Fig. 2).
The MAb1D5 and MAb5 monoclonal antibodies
were tested in parallel with four sera derived from
BSP patients on a Western blot. The MAb1D5
reacted strongly with two protein bands of approxi-
mately 100 kDa MW and less strongly with a27kDa
protein. The MAb5 gaveno reactivity on the blot
(Fig. 4). The anti-MMP-9 antibodies were tested in
parallel with two BSP sera on a Western blot and the
anti-MMP-9 antibodies reacted with proteins of 27,
50 and 75–100 kDa MW (Fig. 5).
The MAb1D5, MAb5, anti-MMP-9 were tested in par-
allel on a Western blot, using a 7.5 % gel in an attempt
to separate out the bands around 75-100 kDa MW, and
this demonstrated that the MAb1D5 antibody reacted
with a protein closer to 100 kDa MW compared to the
anti-MMP-9 that reacted with a protein of approximately
80 kDa (Additional file 1: Figure S1). Both antibodies
reacted with a protein of approximately 25 kDa MW.
A zymogram was run with and without EDTA (metal-
loprotease inhibitor). In the absence of EDTA two
distinct bands above and below the 100 kDa protein
marker (approximately 95 and 105 kDa, respectively)
were apparent. Addition of EDTA to the zymogram
abolished these two bands (Additional file 2: Figure S2).
Discussion
Serum IgA levels were found to be significantly lower in
subjects that were positive for Blastocystis sp. even after
adjusting for the confounding variables of gender, age,
season and Asian ethnicity that have been reported to
influence serum IgA levels [35, 37]. The level of IgA cor-
related with carriage but not symptoms suggesting that a
low serum IgA may permit Blastocystis sp. to establish
in the gut lumen but may not influence pathogenicity.
The association of Blastocystis carriage and low serum
IgA would be consistent with the fact that IgA is the
major immunoglobulin class involved in mucosal de-
fence [38] and is known to prevent adherence of patho-
gens to the gut luminal surface, bind toxins and inhibit
antigen absorption. IgA production increases after three
months of age in parallel with the change from a sterile
gut to one with a complex commensal intestinal micro-
biota [39]. Secretory IgA can be effective against patho-
gens as an innate non-specific local response or develop
into an adaptive specific systemic response after presenta-
tion of luminal antigen to gut associated lymphoid tissue
(GALT) and subsequent generation of IgA-producing
plasma cells in the intestinal mucosa. The complex rela-
tionship of IgA to the regulation or monitoring of the in-
testinal microbiota is not understood. Proteases derived
from Blastocystis cell lysates have been shown to be cap-
able of degrading secretory IgA [28].
Low serum levels of IgA may be due to a number of
causes including partial or complete selective IgA defi-
ciency [40] and likely influence host and microbial inter-
actions. IgA deficiency is associated with an increased
risk of giardiasis (caused by another non-invasive
luminal parasite) as well as respiratory infections and al-
lergic and autoimmune diseases [38]. Patients with auto-
immune diseases and selective IgA deficiency more
commonly exhibit the major histocompatibility complex
(MHC) haplotype 8.1 and other non-MHC gene defects
have been reported [41].
IgG serum antibodies from many study participants in
all subgroups reacted with proteins of approximately 27,
50, 60–65, 75–90, 95–105, and 150 kDa MW in the
Fig. 3 Serum antibodies from Blastocystis negative clinical subgroups IBS-N and HC-N reacting with Blastocystis proteins in Western blot
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Fig. 5 Serum antibodies in IBS-P clinical subgroup and MAb anti-proMMP-9 reacting with Blastocystis proteins in Western blot
Fig. 4 Serum antibodies from clinical subgroup IBS-P and monoclonal antibodies MAb1D5 and MAb5 reacting with Blastocystis proteins in
Western blot
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Western blots using axenic WR1 (ST4) as antigen
source. Although differences in the quantity or affinity
of the antibodies were suggested by the intensity of the
signals, no attempt was made to apply quantitation by
densitometry. The rabbit-derived Blastofluor® antibody,
raised in rabbits primed with axenic ST3, showed a very
similar reactivity pattern to proteins of 10, 17, 27, 37, 50,
75, 100 KDa MW when tested in parallel with human
sera (Fig. 2), suggesting that these particular Blastocystis
antigens are common to both subtypes 3 and 4. Whilst
some researchers have described different SDS-PAGE
protein patterns in different Blastocystis organisms [42,
43] others have found little difference in the protein
sizes between different Blastocystis subtypes [31, 44].
Over 40 % of healthy asymptomatic patients negative
for Blastocystis sp. reacted to Blastocystis antigens at 27,
50, 60–65 and 75-90 kDa, respectively (Table 3), suggest-
ing that positive reactions with these proteins occurred
either due to past exposure to Blastocystis sp. or as a re-
sult of a cross reactivity with the Blastocystis antigens.
Only the antibody band sizes 95–105 and 150kDA were
significantly more common in those with current car-
riage of Blastocystis sp., occurring in approximately 60 %
of these individuals.
However, IBS groups, either positive or negative for
Blastocystis carriage, when compared to HC displayed a
different pattern with significantly higher number of re-
actions to 27, 50 and 75-95kDaMW proteins. Overall
these proteins were present in approximately 86-100 %
of IBS patients compared to 44-71 % of HC. Although
presence of these proteins was greatest in the Blasto-
cystis-positive IBS group, it was still present in the
IBS group negative for current carriage of Blastocystis
sp.. This finding again suggests the positive reactions
in the IBS-N group were either due to non-specific
antibody cross-reactions or due to residual antibody
from past exposure to Blastocystis organisms. The gut
epithelial permeability is increased in IBS [7, 45] and
it is probable that IBS patients have greater exposure
to intraluminal antigens. Although the number of
subjects in our clinical subgroups was relatively small
our findings suggest that exploration of the nature of
these 27, 50, 75-95 kDa MW proteins may be useful
in identifying biomarkers for IBS (current biomarkers
are not able to reliably exclude organic disease [4]),
identifying patients who are symptomatic due to Blas-
tocystis infection and informing development of effective
therapies.
Several studies have reported that an antigenic protein
with a MW of approximately 30 kDa is present in Blas-
tocystis organisms [17, 46] and differences in reactivity
to this protein(s) between symptomatic patients and
healthy controls have been reported [17, 47]. No reactiv-
ity with proteins of this size was reported in sera from
patients with other parasitic infections suggesting the
30 kDa protein might be specific for Blastocystis or-
ganisms. A cytopathic monoclonal antibody, MAb1D5,
previously shown to bind to the external surface of
Blastocystis sp. [32], reacts with a30kDa protein from
Blastocystis isolates derived from humans (ST’s un-
known), but reportedly not with antigen derived from
WR1 [24]. Peptide sequences derived from material
obtained by 2-dimensional electrophoresis and Western
blotting suggest that this 30 kDa protein is closely related
to a cysteine protease of the legumain type. Although no
reactivity of the MAb1D5 was reported previously with
subtype WR1 [24],and this was the subtype we used as an
antigen source in our study, the 27 kDa protein-reactivity
that we observed more frequently in the symptomatic
group may nevertheless correspond to this previously de-
scribed 30 kDa protein. The difference in reactivity may
be accounted for by increased purity of MAb1D5 used in
our study and differences in antigen preparation tech-
nique, and the MW size difference accounted for by differ-
ences in Blastocystis antigen source and preparation (e.g.,
subtype, level of glycosylation). The MAb1D5 tested in
parallel with our human serum samples reacted strongly
with a double band around 100 kDa MW and also with a
27 kDa protein in the Western blots (Fig. 4). This pattern
of reactivity (100 and ~30 kDa) against an antigen prepar-
ation using ST7 organisms was shown previously [27] and
suggests that the 30 kDa antigen may be a processed or
degraded form of the 100 kDa protein.
We also noted differences in IBS patients (IBS-P
and IBS-N) with regard to reactivity to 50 and 75-
95 kDa proteins. These proteins may correspond to
the 50 and 118 kDa antigens [17], or the 60-100 kDa
sized proteases [48] reported previously in symptom-
atic Blastocystis infected patients. Parasitic proteases
are known to be highly immunogenic and may facili-
tate tissue invasion in the host. We searched for a
protease that might be consistent with this role and
sizes. Matrix metalloproteinase-9 (MMP-9) is one
member of the zinc binding matrix metalloproteinases
(MMP) that degrade components of the extracellular
matrix including gelatin (gelatinase B), collagens, and
elastin, thereby potentially aiding tissue invasion
[49],and has been shown to interact with the immune
system including potentiation of IL-8 [49]. MMP-9’s
are found in the cytosol, vesicles and cell membranes
of cells [50]. They exist as a pro-enzyme at around
92 kDa, an activated form around 84 kDa and trun-
cated forms at lower sizes around 50 kDa in humans
[51]. The pro-MMP-9’s are activated by other prote-
ases, detergents and heat. We tested an antibody spe-
cific for human pro-MMP-9 in parallel with human
sera in our Western blots and found that it reacted
with Blastocystis proteins of approximately 75–100,
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50 and 27 kDa MW, respectively, and that the pattern
differed from the MAb1D5 reactivity. MAb1D5 reacted
with a different distinct protein of approximately 95 kDa
as well as a27kDa protein.
A subsequent zymogram performed using antigen that
had been pre-treated with protease inhibitors minus
EDTA showed a positive double band around 100 kDa
that was abolished with EDTA. These findings suggest
that a metalloproteinase around 100 kDa MW is present
in Blastocystis sp.. Inherent differences in gel runs and
species variation of enzymes make it difficult to assess if
this 100 kDa zymogram band is related to the Western
blot 75–95 kDa bands we noted to be of significance in
symptomatic patients. The findings nevertheless suggest
that a MMP-9 isoform is present in Blastocystis organ-
isms, and the pro-MMP-9 band may correspond to the
75–95 kDa protein, while the 50 kDa protein may pos-
sibly be the enzymatically active form and the 27 kDa
form a truncated fragment.
The detection of a 27 kDa protein with both the anti-
MMP-9 and the MAb1D5 suggest that this band may
contain more than one protein, including a truncated
fragment of a MMP-9 isoform. Previous studies investi-
gating proteases present in Blastocystis sp. have sug-
gested that cysteine proteases constitute the major class
of proteases in this organism (80 % protease activity
shown to be inhibited by cysteine protease inhibitors)
[52]. However it may be difficult to account for prote-
ases that are present as pro-enzymes that require activa-
tion or that may be inhibited from converting to active
forms by other proteases. Protease activity at 32 kDa
was reported to be significantly increased in symptom-
atic patients [47, 53] but may be due to a mixture of en-
zymes of that size. The genome of ST7 has been
sequenced and this has allowed the prediction that all
classes of proteases (cysteine, serine and metallopro-
teases) could be secreted by the parasite [26]. The ma-
jority (91 %) are predicted to be of the cysteine protease
and none were specifically predicted, at this level of gen-
ome testing sensitivity, to be a metalloprotease of the
MMP-9 class. Preliminary analysis of the ST4 genome
has shown the presence of up to 30 % genes with no
ortholog present in the ST7 genome [54] emphasising
the genetic diversity present in this organism. Additionally,
a recent study has discovered that 15 % of nuclear genes in
Blastocystis sp. Subtype 7 uniquely use a polyadenylation-
mediated creation of termination codons [55] and predicted
genes may need to be re-evaluated in the light of this new
information.
Conclusions
Low serum IgA levels may facilitate Blastocystis carriage
but are not associated with the development of IBS
gastrointestinal symptoms. Antibodies to Blastocystis
organisms are commonly found in the serum of many
healthy individuals, but antibodies to 27, 50 and 75-
95 kDa MW proteins are significantly increased in IBS
patients regardless of Blastocystis status. Some of these
serum antibodies are likely to be reacting to a previously
reported cysteine protease, but others may be reacting
with another class of proteases, the metalloproteases.
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